| Literature DB >> 32033047 |
Katarina Radosavljevic1, Gordana Dragovic-Lukic2, Dejan Nikolic1,3, Pavle Radovic4, Biljana Milicic5, Natasa Radosavljevic6.
Abstract
The study aim was to evaluate the effects of presence and level of musculoskeletal impairment along with gender on physical functioning outcome after the rehabilitation program in aged adults with a hip fracture. We analyzed 203 elderly people with hip fractures above 65 years of age that were treated after the hip surgery. According to the time of examination, patients were tested three times: at admission, discharge, and at three months post-discharge. Musculoskeletal impairments were analyzed, and for the estimation of severity of degree impairment, we used a cumulative index rating scale for geriatrics (CIRS-G). Regarding the gender, we separately analyzed males and females. To evaluate physical functioning of aged adults after a hip fracture, we used the physical functioning component (PFC) from the quality of life (SF-36) questionnaire. For males, on all three occasions we found non-significant differences were found in SF-36 PFC values between different degrees of CIRS-G musculoskeletal impairment. A significant difference was noticed in females three months post-discharge. Effects size of different examination periods for every CIRS-G severity degree of musculoskeletal impairment were high, where males had higher values for severity degrees 1 and 2, and females had higher values for severity degrees 0 and 3. Our findings might suggest that there is a certain degree of different rehabilitation treatment effects for males versus females. Moreover, it might be assumed that other factors could influence different degrees of functional improvement and outcome of individuals after a hip fracture with musculoskeletal impairment.Entities:
Keywords: aged adults; gender; musculoskeletal comorbidity; physical functioning; rehabilitation
Year: 2020 PMID: 32033047 PMCID: PMC7151143 DOI: 10.3390/healthcare8010031
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Frequencies of comorbidities.
| CIRS-G | Musculoskeletal Impairment | |||
|---|---|---|---|---|
| Total | Males | Females | Males/Females | |
| 0 | 62 | 17 (27.4) | 45 (72.6) | 0.141 |
| 1 | 75 | 15 (20.0) | 60 (80.0) | |
| 2 | 37 | 15 (40.5) | 22 (59.5) | |
| 3 | 29 | 7 (24.1) | 22 (75.9) | |
| 4 | 0 | 0 (0) | 0 (0) | |
| ∑ | 203 | 54 (26.6) | 149 (73.4) | - |
* Chi squared test.
SF-36 PFC mean values in different time of observation for separate CIRS-G parameters regarding severity degree.
| Study Participants | CIRS-G (Degree) | Period of Observation | |||
|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | |||
|
| 0 | 30.65 ± 9.90 | 58.95 ± 13.00 | 69.11 ± 13.84 | 0.000 |
| 1 | 26.53 ± 9.69 | 53.27 ± 13.62 | 61.93 ± 15.62 | 0.000 | |
| 2 | 25.00 ± 10.14 | 53.24 ± 11.80 | 60.54 ± 15.13 | 0.000 | |
| 3 | 25.17 ± 9.01 | 51.90 ± 14.04 | 58.97 ± 15.55 | 0.000 | |
|
| 0.018 | 0.028 | 0.004 | ||
|
| 0 | 30.00 ± 10.61 | 57.94 ± 13.93 | 67.35 ± 14.91 | 0.000 |
| 1 | 30.33 ± 8.34 | 56.33 ± 10.08 | 64.67 ± 12.88 | 0.000 | |
| 2 | 22.00 ± 11.15 | 52.67 ± 11.32 | 59.33 ± 15.57 | 0.000 | |
| 3 | 22.86 ± 8.09 | 48.57±12.49 | 53.57 ± 18.42 | 0.000 | |
|
| 0.053 | 0. 286 | 0.181 | ||
|
| 0 | 30.89 ± 9.73 | 59.33 ± 12.77 | 69.78 ± 13.52 | 0.000 |
| 1 | 25.58 ± 9.83 | 52.50 ± 14.34 | 61.25 ± 16.25 | 0.000 | |
| 2 | 27.05 ± 9.08 | 53.64 ± 12.36 | 61.36 ± 15.13 | 0.000 | |
| 3 | 25.91 ± 9.34 | 52.95 ± 14.61 | 60.68 ± 14.58 | 0.000 | |
|
| 0.058 | 0.084 | 0.022 | ||
MV: mean value; SD: standard deviation; Med: median; IQR: inter quartile range; * Friedman test; ** Kruskal Wallis test.
Figure 1Mean values with 95% CI of physical functioning component (PFC) SF-36 for different CIRS-G degrees on three occasions in: (a) females; (b) males.
Relative variability and effect sizes of evaluated parameters in study sample.
| Study Participants | CIRS-G (Degree) | Variability (V-%) | η2 (%) | ||
|---|---|---|---|---|---|
| Admission | Discharge | 3 months | |||
|
| 0 | 32.30 | 22.05 | 20.02 | 63.78 |
| 1 | 36.52 | 25.57 | 25.22 | 66.97 | |
| 2 | 40.56 | 22.16 | 24.99 | 60.59 | |
| 3 | 35.80 | 27.05 | 26.37 | 55.87 | |
|
| 5.35 | 4.38 | 6.39 | ||
|
| 0 | 35.37 | 24.04 | 22.14 | 60.26 |
| 1 | 27.50 | 17.89 | 19.92 | 67.10 | |
| 2 | 50.68 | 21.50 | 26.24 | 63.19 | |
| 3 | 35.39 | 25.72 | 34.38 | 53.05 | |
|
| 14.22 | 7.00 | 9.44 | ||
|
| 0 | 31.50 | 21.52 | 19.38 | 65.29 |
| 1 | 38.43 | 27.31 | 26.53 | 55.38 | |
| 2 | 33.57 | 23.04 | 24.66 | 59.39 | |
| 3 | 36.05 | 27.59 | 24.03 | 57.64 | |
|
| 5.61 | 4.75 | 6.65 | ||
Correlations of SF-36 PFC values in defined severity degree of CIRS-G regarding the time of observation.
| Study Participants | CIRS-G (Degree) | Time Groups | Admission | Discharge |
|---|---|---|---|---|
| Overall | 0 | Discharge | 0.000 | |
| 3 months | 0.000 | 0.000 | ||
| 1 | Discharge | 0.000 | ||
| 3 months | 0.000 | 0.000 | ||
| 2 | Discharge | 0.000 | ||
| 3 months | 0.000 | 0.000 | ||
| 3 | Discharge | 0.000 | ||
| 3 months | 0.000 | 0.000 | ||
| Male | 0 | Discharge | 0.000 | |
| 3 months | 0.000 | 0.000 | ||
| 1 | Discharge | 0.001 | ||
| 3 months | 0.001 | 0.001 | ||
| 2 | Discharge | 0.001 | ||
| 3 months | 0.001 | 0.010 | ||
| 3 | Discharge | 0.018 | ||
| 3 months | 0.018 | 0.083 | ||
| Female | 0 | Discharge | 0.000 | |
| 3 months | 0.000 | 0.000 | ||
| 1 | Discharge | 0.000 | ||
| 3 months | 0.000 | 0.000 | ||
| 2 | Discharge | 0.000 | ||
| 3 months | 0.000 | 0.000 | ||
| 3 | Discharge | 0.000 | ||
| 3 months | 0.000 | 0.000 |
* Willcoxon test.